文献速递湿疹皮炎与荨麻疹

Orismilast治疗中重度特应性皮炎的IIb期剂量探索研究

Orismilast, a phosphodiesterase 4B/D inhibitor, in moderate-to-severe atopic dermatitis: efficacy and safety from a multicentre randomized placebo-controlled phase IIb dose-ranging study (ADESOS).
PubMed 文献 · Br J Dermatol · 2025-01-01

这项16周、多中心、随机、安慰剂对照的IIb期剂量探索研究(ADESOS,NCT05469464)纳入欧洲和美国48个中心的233例中重度特应性皮炎成人患者,按1:1:1:1随机接受orismilast 20 mg、30 mg、40 mg或安慰剂每日两次。主要终点EASI百分比变化在各orismilast组与安慰剂组间差异无统计学意义(P > 0.05);20 mg和40 mg组达到IGA 0/1且改善≥2分的患者显著多于安慰剂(P < 0.05);第2周时orismilast组达到PP-NRS下降≥4分的患者比例显著更高。安全性特征与PDE4类一致,未报告重大安全性问题。

要点

  • orismilast 20 mg和40 mg每日两次显著提高第16周IGA 0/1且改善≥2分的患者比例。
  • 第2周时orismilast组达到PP-NRS下降≥4分的患者比例显著高于安慰剂。
  • 主要终点EASI百分比变化在各orismilast组与安慰剂组间差异无统计学意义(P > 0.05)。

核心结论

  • 数据支持选择性PDE4B/D抑制的临床相关性,orismilast可能成为治疗特应性皮炎的一种便捷新型口服疗法。

研究设计与样本

  • 16周、多中心、随机、安慰剂对照的IIb期剂量探索研究(NCT05469464),纳入欧洲和美国48个中心的233例中重度特应性皮炎成人患者。
  • 患者按1:1:1:1随机接受orismilast 20 mg(n = 58)、30 mg(n = 61)、40 mg(n = 59)或安慰剂(n = 55),每日两次。

主要发现

  • 第16周EASI较基线的百分比变化在各orismilast组和安慰剂组均可见,orismilast与安慰剂比较P > 0.05。
  • 第16周达到IGA 0/1且改善≥2分的患者比例,orismilast 20 mg和40 mg组显著高于安慰剂(P < 0.05)。
  • 第2周达到PP-NRS下降≥4分的患者比例,orismilast组显著更高。
  • 安全性特征与PDE4类一致,未报告重大安全性问题。

关键数值与推荐

  • 主要终点为EASI百分比变化。
  • 次要终点(均在第16周)包括达到IGA 0/1且改善≥2分、PP-NRS下降≥4分、EASI较基线下降75%、90%和100%。

临床怎么用

  • orismilast 20 mg和40 mg每日两次可能改善中重度特应性皮炎患者的皮损清除和早期瘙痒。
  • 需结合剂量探索研究的变异性,谨慎解读不同剂量疗效并指导后续试验剂量选择。

局限性

  • 剂量探索研究将患者分为较小亚组可能导致变异,评估不同剂量疗效及选择进入后续试验的剂量时须考虑此点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by eczematous skin lesions and pruritus. There is an unmet need for effective first-line systemic treatments with good safety profiles, particularly oral medications. Orismilast is a novel first-in-class oral phosphodiesterase 4 (PDE4) B/D inhibitor under investigation for the treatment of moderate-to-severe AD. OBJECTIVES: To evaluate the optimal dose, efficacy and safety of twice-daily orismilast in patients with moderate-to-severe AD. METHODS: This 16-week, multicentre randomized placebo-controlled phase IIb dose-ranging study (NCT05469464) included patients from 48 centres in Europe and the USA. Adults with moderate-to-severe AD were given (1 : 1 : 1 : 1) orismilast 20 mg, 30 mg or 40 mg, or placebo, twice daily. The primary endpoint was percentage change in Eczema Area and Severity Index (EASI); the secondary endpoints (all at week 16) included achievement of a score of clear (0) or almost clear (1) with ≥ 2-point improvement on the Investigator Global Assessment (IGA 0/1); achievement of a Peak Pruritus Numerical Rating Scale (PP-NRS) reduction of ≥ 4 points; and achievement of a reduction in EASI of 75%, 90% and 100% from baseline. RESULTS: Overall, 233 patients were randomly assigned to orismilast 20 mg (n = 58), 30 mg (n = 61), 40 mg (n = 59) or placebo (n = 55). At week 16, reductions in EASI (percentage points) from baseline to week 16 were seen across orismilast groups and placebo (P > 0.05 for orismilast vs. placebo). Significantly more patients achieved IGA 0/1 with a ≥ 2-point improvement with orismilast 20 mg and 40 mg compared with placebo (P < 0.05). Significantly greater proportions of patients achieving a ≥ 4-point reduction in PP-NRS were demonstrated with orismilast at week 2. The safety profile was consistent with that of the PDE4 class, with no major safety concerns reported. CONCLUSIONS: These data support the clinical relevance of selective PDE4B/D inhibition with orismilast, potentially offering a convenient, novel oral therapy for the treatment of AD. Atopic dermatitis (‘AD’ for short) is also known as eczema. It is a common condition that causes red, itchy and inflamed skin. It also affects a person’s immune system. We aimed to find the best dose of a new medication called ‘orismilast’. We also wanted to check how well it works and how safe it is for adults with moderate-to-severe AD. For 16 weeks, people with AD were randomly given either 20, 30 or 40 milligrams of orismilast twice a day, or a placebo (a pill with no active medication). We measured how well the treatment worked by looking at the number of people whose skin cleared up or almost cleared up and how much itching was reduced. We used a measurement tool called the ‘EASI’ to monitor improvements. We also looked for side effects to check the medication’s safety. By week 16, more people who took 20 or 40 milligram doses of orismilast had clearer skin than those taking the placebo. People who took orismilast also reported less itching as early as week 2. Improvements in EASI score were seen across all the groups, including those taking placebo. The side effects were similar to those seen with other similar medications. Studies that divide patients into smaller groups to test different doses can lead to variation. This must be considered when assessing how well different doses of a medication work and which doses should be taken into the next trials. We suggest that orismilast could be a promising new treatment for people with AD.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Silverberg JI, Eichenfield LF, Blauvelt A, et al. Orismilast, a phosphodiesterase 4B/D inhibitor, in moderate-to-severe atopic dermatitis: efficacy and safety from a multicentre randomized placebo-controlled phase IIb dose-ranging study (ADESOS). Br J Dermatol. 2025. PMID: 39847538. doi:10.1093/bjd/ljae507

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。